Study wrapper · #1165
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Editor's note
The gap between the animal literature and the human literature is the whole story here. Animal models show a consistent anti-inflammatory effect, while the two human cohorts — 109 patients between them — show metabolic changes and no measurable effect on disability or relapse. The pharmacovigilance reporting ratios are a weak instrument and should not be read as protective. The useful takeaway is that no randomized trial exists yet, and the authors say so plainly.
Plain-language abstract
This registered systematic review pulled together everything published on GLP-1 receptor agonists in multiple sclerosis: fifteen studies, of which eight were animal experiments, four were observational human studies, and three provided narrative context. In animal models of MS, GLP-1 agonists reliably reduced disease severity, with several proposed mechanisms including AMPK/SIRT1 activation, NLRP3 suppression, and shifts in T-cell and microglial activity. The human data are much thinner: two small cohorts totaling 109 patients showed lower BMI and higher vitamin D but no change in disability scores or relapse rates, a survey of 4,181 patients found 7.4% had ever used one, and pharmacovigilance reporting ratios for semaglutide, dulaglutide, and liraglutide were below one. A Mendelian randomization analysis found no causal link between GLP-1 receptor activation and MS susceptibility. The authors rate most animal studies as high risk of bias and the human studies as moderate to high, and call for randomized trials.